LONDON and SALT LAKE CITY - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), a diagnostics company, has released a study showing that its KidneyIntelX in vitro prognostic testing is associated with significant improvements in the management of chronic kidney disease (CKD) and Type 2 diabetes. The study, which followed 2,569 patients with Type 2 diabetes and diabetic kidney disease (DKD) over 12 months, found a 61% increase in preventative drug prescriptions among high-risk patients and more effective specialist referrals.
The study's diverse cohort, which included 27% black patients, demonstrated that the integration of KidneyIntelX into electronic health records led to a slower progression of CKD and better control of Type 2 diabetes, particularly in patients at the highest risk. These patients also showed improved blood pressure control, which is linked to better cardiovascular health outcomes in CKD.
KidneyIntelX has achieved broad insurance payment coverage, including through Medicare, Medicaid, and Blue Cross Blue Shield programs. The FDA granted the test a de Novo Marketing Authorization in June 2023 for an indicated use addressable market of approximately 14 million patients with adult diabetes and kidney disease.
Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix, emphasized the significance of the findings for preventative medicine in chronic diseases. CEO James McCullough highlighted the importance of adopting KidneyIntelX across primary care networks to address the burden of chronic diseases.
The study included patients with various high-risk factors for disease progression, with the majority being treated by their primary care physician. The real-world evidence supports the use of KidneyIntelX for early risk assessment and intervention to improve healthcare outcomes and control costs.
Renalytix, which specializes in bioprognosis™ for kidney health, believes that early action based on KidneyIntelX testing can improve patient outcomes and reduce health system costs. The company plans to continue publishing data to support the use of its test in clinical practice.
This report is based on a press release statement from Renalytix plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.